2024-12-14 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co. (LLY), a leading pharmaceutical company, based on the provided data.


**1. Performance vs. S&P 500 (VOO):**

Eli Lilly (LLY) significantly outperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for LLY is 574.84%, while the VOO's cumulative return is 120.91%. This represents a difference of 453.9 percentage points. The relative divergence places LLY's performance in the 72.6th percentile of its historical range compared to the S&P 500.  The provided CAGR (Compound Annual Growth Rate) data further highlights LLY's superior performance consistently exceeding the market over several years.


**2. Recent Price Movement:**

* **Closing Price:** $789.12
* **5-Day Moving Average:** $794.13
* **20-Day Moving Average:** $782.41
* **60-Day Moving Average:** $845.56

The stock price is currently below its 5-day and 60-day moving averages, suggesting a short-term downtrend, but above its 20-day moving average, indicating some support.  The last market price of $789.34 doesn't indicate a significant jump or drop.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 64.63 – Suggests the stock is neither overbought nor oversold.
* **PPO (Price Oscillator):** 0.38 – A positive value indicates bullish momentum.
* **20-Day Relative Divergence Change:** -4.7% - Shows a recent slight weakening in relative performance.
* **Expected Return:** 555.1% - This represents a significant outperformance of the S&P 500 over the long term (2+ years) assuming current trends continue.  This is a projection and not a guarantee.


**4. Recent Earnings Analysis:**

The provided earnings data shows considerable fluctuation in EPS, with a significant jump in Q2 2024 ($3.29) followed by a decline in Q3 2024 ($1.08).  Revenue remains relatively consistent, hovering around $11B in recent quarters, with a dip in Q1 2024 ($8.77B). There's a significant negative EPS in Q4 2023 and Q4 2024 (-$0.06), requiring further investigation to understand the cause.  Note: The table contains duplicate data for Q4 2024.


**5. Financial Information:**

* **Revenue:** Revenue is relatively stable, with slight fluctuations.
* **Profit Margin:** Remains consistently high, around 80%, indicating strong profitability.
* **Equity:** Shows growth, reflecting a healthy financial position.
* **ROE (Return on Equity):**  Highly volatile, indicating possible short-term fluctuations in profitability and efficiency.  Note the significant negative ROE in Q3 2023.


**6. News and Recent Issues:**

This section requires further information as no recent news or analyst opinions were provided in the initial prompt.


**7. Overall Analysis:**

Eli Lilly (LLY) demonstrates strong historical outperformance compared to the S&P 500, supported by consistently high profit margins and revenue. However, recent earnings show volatility in EPS, and  the fluctuating ROE warrants closer examination.  Technical indicators point to a potential short-term slowdown, but the long-term outlook, according to the provided data, remains optimistic with a high projected excess return over the S&P 500.  Additional information regarding recent news, analyst opinions, and the causes of the negative EPS figures and fluctuating ROE are crucial for a more comprehensive assessment.


**8. Disclaimer:**

This report is based solely on the data provided. It is not financial advice and should not be the sole basis for investment decisions.  Conduct thorough independent research and consider consulting a financial advisor before making any investment choices.
